GLP-1 Receptor Agonists Cut Heart Attack Risk and Reshape Cardiovascular Care

Cardiovascular disease remains the leading cause of death in people with type 2 diabetes, making the cardiovascular profile of glucose-lowering drugs a critical clinical concern. This 2026 review by Kahles, Birkenfeld, and Marx in the Journal of Clinical Investigation provides a thorough synthesis of how the incretin hormone GLP-1 and its pharmacological agonists affect the cardiovascular system, spanning preclinical mechanistic studies to large-scale clinical outcomes trials.

In preclinical atherosclerosis models, both native GLP-1(7–36) amide and GLP-1RAs such as exendin-4, liraglutide, semaglutide, and dulaglutide consistently reduced atherosclerotic lesion size, stabilized plaque morphology (thicker fibrous caps, reduced necrotic cores), suppressed ICAM-1 expression, decreased foam cell formation, and curtailed myeloid cell infiltration into vessel walls. Crucially, these effects occurred independently of changes in LDL cholesterol, blood glucose, or body weight. Emerging evidence suggests GLP-1RAs also dampen systemic inflammation—reducing circulating Ly-6Chi monocytes, neutrophils, TNF-α, and IFN-γ—possibly by suppressing bone marrow hematopoiesis. The cellular targets mediating these effects remain incompletely defined; GLP-1R expression on most immune cells is very low, and anti-atherosclerotic effects of semaglutide were preserved in mice lacking GLP-1R on endothelial and hematopoietic cells.

In heart failure models spanning mice, rats, pigs, and dogs, GLP-1R agonism improved cardiac output during ischemia, reduced infarct size, attenuated myocardial inflammation, and activated cardioprotective signaling pathways including PI3K/Akt, AMPK, and PKC/S100A9. In HFpEF mouse models, liraglutide and semaglutide reduced LV hypertrophy, fibrosis, and diastolic dysfunction beyond what was achieved by dietary weight loss alone, indicating direct cardiac effects. GLP-1 metabolites lacking classical GLP-1R binding (e.g., GLP-1[28–36]) also showed cardioprotection, suggesting receptor-independent pathways deserve further investigation. Species differences in cardiac GLP-1R expression—atrial-predominant in mice versus both atrial and ventricular in humans—complicate direct translation.

Clinically, eleven major CVOTs have evaluated GLP-1RAs on MACE (CV death, nonfatal MI, nonfatal stroke). A meta-analysis across these trials showed a 14% relative risk reduction (HR 0.86; 95% CI 0.80–0.93), rising to 15% when the neutral ELIXA trial (lixisenatide, short-acting) is excluded. The recently completed SOUL trial confirmed that oral semaglutide reduces MACE by 14% (HR 0.86; p=0.006), extending CV benefit to an oral formulation. The SELECT trial notably demonstrated CV benefit of injectable semaglutide in people with obesity and established cardiovascular disease but without diabetes, broadening the therapeutic indication beyond T2D. DPP-4 inhibitors demonstrated cardiovascular safety but no superiority over placebo. Tirzepatide (dual GLP-1R/GIPR agonist) achieves greater HbA1c reduction and weight loss than GLP-1RAs alone; its hard cardiovascular endpoint data are awaited from ongoing CVOTs.

Despite compelling evidence, important questions remain. The molecular mechanisms underlying CV protection—particularly the relative contributions of direct vascular effects, systemic anti-inflammation, metabolic improvement, and weight loss—are not fully resolved. Conditional knockout models and human mechanistic studies will be essential. Additionally, the clinical relevance of GLP-1R–independent effects, optimal patient selection, and long-term safety in non-diabetic populations require further study.